Shannan Henry
Program Manager 1
Research & Publications
Biography
Coauthors
Selected Publications
- 573. Distinct Pattern of Synaptic Loss in Parkinson’s Disease DepressionYang Y, Naganawa M, Honhar P, Tinaz S, Dias M, Henry S, Ropcham J, Comley R, Nabulsi N, Huang Y, Carson R, Finnema S, Matuskey D, Holmes S. 573. Distinct Pattern of Synaptic Loss in Parkinson’s Disease Depression. Biological Psychiatry 2023, 93: s326. DOI: 10.1016/j.biopsych.2023.02.813.
- Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adultsMatuskey D, Gallezot J, Nabulsi N, Henry S, Torres K, Dias M, Angarita G, Huang Y, Shoaf S, Carson R, Mehrotra S. Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults. Journal Of Psychopharmacology 2022, 37: 164-171. PMID: 36515395, PMCID: PMC9912308, DOI: 10.1177/02698811221140008.
- Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2ANaganawa M, Gallezot J, Finnema S, Maguire R, Mercier J, Nabulsi N, Kervyn S, Henry S, Nicolas J, Huang Y, Chen M, Hannestad J, Klitgaard H, Stockis A, Carson R. Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A. EJNMMI Research 2022, 12: 71. PMID: 36346513, PMCID: PMC9643320, DOI: 10.1186/s13550-022-00944-5.
- Age, gender and body-mass-index relationships with in vivo CB1 receptor availability in healthy humans measured with [11C]OMAR PETRadhakrishnan R, Worhunsky PD, Zheng MQ, Najafzadeh S, Gallezot JD, Planeta B, Henry S, Nabulsi N, Ranganathan M, Skosnik PD, Pittman B, Cyril D'Souza D, Carson RE, Huang Y, Potenza MN, Matuskey D. Age, gender and body-mass-index relationships with in vivo CB1 receptor availability in healthy humans measured with [11C]OMAR PET. NeuroImage 2022, 264: 119674. PMID: 36243269, DOI: 10.1016/j.neuroimage.2022.119674.
- Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer 11C-TASP699Naganawa M, Nabulsi NB, Matuskey D, Henry S, Ropchan J, Lin SF, Gao H, Pracitto R, Labaree D, Zhang MR, Suhara T, Nishino I, Sabia H, Ozaki S, Huang Y, Carson RE. Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer 11C-TASP699. Journal Of Nuclear Medicine 2021, 63: 609-614. PMID: 34385336, DOI: 10.2967/jnumed.121.262430.
- Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2ALi S, Naganawa M, Pracitto R, Najafzadeh S, Holden D, Henry S, Matuskey D, Emery PR, Cai Z, Ropchan J, Nabulsi N, Carson RE, Huang Y. Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A. European Journal Of Nuclear Medicine And Molecular Imaging 2021, 48: 1327-1338. PMID: 33416954, DOI: 10.1007/s00259-020-05149-3.
- First-in-Human Evaluation of 18F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2ANaganawa M, Li S, Nabulsi N, Henry S, Zheng MQ, Pracitto R, Cai Z, Gao H, Kapinos M, Labaree D, Matuskey D, Huang Y, Carson RE. First-in-Human Evaluation of 18F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2A. Journal Of Nuclear Medicine 2020, 62: 561-567. PMID: 32859701, PMCID: PMC8049363, DOI: 10.2967/jnumed.120.249144.
- First-in-Human Assessment of 11C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET RadiotracerNaganawa M, Nabulsi N, Henry S, Matuskey D, Lin SF, Slieker L, Schwarz AJ, Kant N, Jesudason C, Ruley K, Navarro A, Gao H, Ropchan J, Labaree D, Carson RE, Huang Y. First-in-Human Assessment of 11C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer. Journal Of Nuclear Medicine 2020, 62: 553-560. PMID: 32859711, PMCID: PMC8049371, DOI: 10.2967/jnumed.120.246967.
- Kinetic Modeling and Test–Retest Reproducibility of 11C-EKAP and 11C-FEKAP, Novel Agonist Radiotracers for PET Imaging of the κ-Opioid Receptor in HumansNaganawa M, Li S, Nabulsi N, Lin SF, Labaree D, Ropchan J, Gao H, Mei M, Henry S, Matuskey D, Carson RE, Huang Y. Kinetic Modeling and Test–Retest Reproducibility of 11C-EKAP and 11C-FEKAP, Novel Agonist Radiotracers for PET Imaging of the κ-Opioid Receptor in Humans. Journal Of Nuclear Medicine 2020, 61: 1636-1642. PMID: 32169917, PMCID: PMC9364890, DOI: 10.2967/jnumed.119.227694.
- Synaptic Changes in Parkinson Disease Assessed with in vivo ImagingMatuskey D, Tinaz S, Wilcox KC, Naganawa M, Toyonaga T, Dias M, Henry S, Pittman B, Ropchan J, Nabulsi N, Suridjan I, Comley RA, Huang Y, Finnema SJ, Carson RE. Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging. Annals Of Neurology 2020, 87: 329-338. PMID: 31953875, PMCID: PMC7065227, DOI: 10.1002/ana.25682.
- In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PETRadhakrishnan R, Matuskey D, Nabulsi N, Gaiser E, Gallezot JD, Henry S, Planeta B, Lin SF, Ropchan J, Huang Y, Carson RE, D'Souza DC. In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET. Psychiatry Research Neuroimaging 2019, 295: 111007. PMID: 31760336, DOI: 10.1016/j.pscychresns.2019.111007.
- Social status and demographic effects of the kappa opioid receptor: a PET imaging study with a novel agonist radiotracer in healthy volunteersMatuskey D, Dias M, Naganawa M, Pittman B, Henry S, Li S, Gao H, Ropchan J, Nabulsi N, Carson RE, Huang Y. Social status and demographic effects of the kappa opioid receptor: a PET imaging study with a novel agonist radiotracer in healthy volunteers. Neuropsychopharmacology 2019, 44: 1714-1719. PMID: 30928993, PMCID: PMC6785144, DOI: 10.1038/s41386-019-0379-7.
- A single‐center, open‐label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteersFinnema SJ, Rossano S, Naganawa M, Henry S, Gao H, Pracitto R, Maguire RP, Mercier J, Kervyn S, Nicolas J, Klitgaard H, DeBruyn S, Otoul C, Martin P, Muglia P, Matuskey D, Nabulsi NB, Huang Y, Kaminski RM, Hannestad J, Stockis A, Carson RE. A single‐center, open‐label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. Epilepsia 2019, 60: 958-967. PMID: 30924924, PMCID: PMC6532410, DOI: 10.1111/epi.14701.
- Imaging the Enzyme 11β-Hydroxysteroid Dehydrogenase Type 1 with PET: Evaluation of the Novel Radiotracer 11C-AS2471907 in Human BrainGallezot JD, Nabulsi N, Henry S, Pracitto R, Planeta B, Ropchan J, Lin SF, Labaree D, Kapinos M, Shirali A, Lara-Jaime T, Gao H, Matuskey D, Walzer M, Marek GJ, Bellaire S, Yuan N, Carson RE, Huang Y. Imaging the Enzyme 11β-Hydroxysteroid Dehydrogenase Type 1 with PET: Evaluation of the Novel Radiotracer 11C-AS2471907 in Human Brain. Journal Of Nuclear Medicine 2019, 60: 1140-1146. PMID: 30877174, DOI: 10.2967/jnumed.118.219766.
- 2181 Age-related change in 5-HT6 receptor availability in healthy male volunteers measured with 11C-GSK215083 PETRadhakrishnan R, Nabulsi N, Gaiser E, Gallezot J, Henry S, Planeta B, Lin S, Ropchan J, Williams W, Morris E, D’Souza D, Huang Y, Carson R, Matuskey D. 2181 Age-related change in 5-HT6 receptor availability in healthy male volunteers measured with 11C-GSK215083 PET. Journal Of Clinical And Translational Science 2018, 2: 3-4. PMCID: PMC6799074, DOI: 10.1017/cts.2018.44.
- Age-Related Change in 5-HT6 Receptor Availability in Healthy Male Volunteers Measured with 11C-GSK215083 PETRadhakrishnan R, Nabulsi N, Gaiser E, Gallezot JD, Henry S, Planeta B, Lin SF, Ropchan J, Williams W, Morris E, D'Souza DC, Huang Y, Carson RE, Matuskey D. Age-Related Change in 5-HT6 Receptor Availability in Healthy Male Volunteers Measured with 11C-GSK215083 PET. Journal Of Nuclear Medicine 2018, 59: 1445-1450. PMID: 29626125, PMCID: PMC6126437, DOI: 10.2967/jnumed.117.206516.
- Preclinical to Clinical Translation of CNS Transporter Occupancy of TD-9855, a Novel Norepinephrine and Serotonin Reuptake InhibitorSmith J, Patil D, Daniels O, Ding YS, Gallezot JD, Henry S, Kim K, Kshirsagar S, Martin W, Obedencio G, Stangeland E, Tsuruda P, Williams W, Carson R, Patil S. Preclinical to Clinical Translation of CNS Transporter Occupancy of TD-9855, a Novel Norepinephrine and Serotonin Reuptake Inhibitor. The International Journal Of Neuropsychopharmacology 2015, 18: pyu027. PMID: 25522383, PMCID: PMC4368888, DOI: 10.1093/ijnp/pyu027.
- Age Effects on Serotonin Receptor 1B as Assessed by PETMatuskey D, Pittman B, Planeta-Wilson B, Walderhaug E, Henry S, Gallezot JD, Nabulsi N, Ding YS, Bhagwagar Z, Malison R, Carson RE, Neumeister A. Age Effects on Serotonin Receptor 1B as Assessed by PET. Journal Of Nuclear Medicine 2012, 53: 1411-1414. PMID: 22851636, PMCID: PMC3690814, DOI: 10.2967/jnumed.112.103598.
- Normative database of the serotonergic system in healthy subjects using multi-tracer PETSavli M, Bauer A, Mitterhauser M, Ding Y, Hahn A, Kroll T, Neumeister A, Haeusler D, Ungersboeck J, Henry S, Isfahani S, Rattay F, Wadsak W, Kasper S, Lanzenberger R. Normative database of the serotonergic system in healthy subjects using multi-tracer PET. NeuroImage 2012, 63: 447-459. PMID: 22789740, DOI: 10.1016/j.neuroimage.2012.07.001.
- Modeling analysis of the new kappa opioid receptor antagonist tracer [11C]LY2795050 in humansTomasi G, Lin S, Zheng M, Planeta-Wilson B, Henry S, Goebl N, Tauscher J, Huang H, Neumeister A, Carson R. Modeling analysis of the new kappa opioid receptor antagonist tracer [11C]LY2795050 in humans. NeuroImage 2010, 52: s39. DOI: 10.1016/j.neuroimage.2010.04.221.
- Serotonin transporter binding after recovery from eating disordersKaye W, Bailer U, Frank G, Henry S, Price J, Meltzer C, Becker C, Ziolko S, Mathis C, Wagner A, Barbarich-Marsteller N, Putnam K. Serotonin transporter binding after recovery from eating disorders. Psychopharmacology 2008, 197: 521-522. DOI: 10.1007/s00213-007-1048-9.
- Serotonin transporter binding after recovery from eating disordersBailer U, Frank G, Henry S, Price J, Meltzer C, Becker C, Ziolko S, Mathis C, Wagner A, Barbarich-Marsteller N, Putnam K, Kaye W. Serotonin transporter binding after recovery from eating disorders. Psychopharmacology 2007, 195: 315-324. PMID: 17690869, DOI: 10.1007/s00213-007-0896-7.
- Exaggerated 5-HT1A but Normal 5-HT2A Receptor Activity in Individuals Ill with Anorexia NervosaBailer U, Frank G, Henry S, Price J, Meltzer C, Mathis C, Wagner A, Thornton L, Hoge J, Ziolko S, Becker C, McConaha C, Kaye W. Exaggerated 5-HT1A but Normal 5-HT2A Receptor Activity in Individuals Ill with Anorexia Nervosa. Biological Psychiatry 2007, 61: 1090-1099. PMID: 17241616, DOI: 10.1016/j.biopsych.2006.07.018.
- Neural correlates of habituation to taste stimuli in healthy womenWagner A, Aizenstein H, Frank G, Figurski J, May J, Putnam K, Fischer L, Bailer U, Henry S, McConaha C, Vogel V, Kaye W. Neural correlates of habituation to taste stimuli in healthy women. Psychiatry Research 2006, 147: 57-67. PMID: 16806849, DOI: 10.1016/j.pscychresns.2005.11.005.
- Personality traits after recovery from eating disorders: Do subtypes differ?Wagner A, Barbarich‐Marsteller N, Frank G, Bailer U, Wonderlich S, Crosby R, Henry S, Vogel V, Plotnicov K, McConaha C, Kaye W. Personality traits after recovery from eating disorders: Do subtypes differ? International Journal Of Eating Disorders 2006, 39: 276-284. PMID: 16528697, DOI: 10.1002/eat.20251.
- Altered Brain Serotonin 5-HT1A Receptor Binding After Recovery From Anorexia Nervosa Measured by Positron Emission Tomography and [Carbonyl11C]WAY-100635Bailer U, Frank G, Henry S, Price J, Meltzer C, Weissfeld L, Mathis C, Drevets W, Wagner A, Hoge J, Ziolko S, McConaha C, Kaye W. Altered Brain Serotonin 5-HT1A Receptor Binding After Recovery From Anorexia Nervosa Measured by Positron Emission Tomography and [Carbonyl11C]WAY-100635. JAMA Psychiatry 2005, 62: 1032-1041. PMID: 16143735, DOI: 10.1001/archpsyc.62.9.1032.
- Normal Brain Tissue Volumes after Long-Term Recovery in Anorexia and Bulimia NervosaWagner A, Greer P, Bailer U, Frank G, Henry S, Putnam K, Meltzer C, Ziolko S, Hoge J, McConaha C, Kaye W. Normal Brain Tissue Volumes after Long-Term Recovery in Anorexia and Bulimia Nervosa. Biological Psychiatry 2005, 59: 291-293. PMID: 16139807, DOI: 10.1016/j.biopsych.2005.06.014.
- Brain imaging of serotonin after recovery from anorexia and bulimia nervosaKaye W, Bailer U, Frank G, Wagner A, Henry S. Brain imaging of serotonin after recovery from anorexia and bulimia nervosa. Physiology & Behavior 2005, 86: 15-17. PMID: 16102788, DOI: 10.1016/j.physbeh.2005.06.019.
- Increased Dopamine D2/D3 Receptor Binding After Recovery from Anorexia Nervosa Measured by Positron Emission Tomography and [11C]RacloprideFrank G, Bailer U, Henry S, Drevets W, Meltzer C, Price J, Mathis C, Wagner A, Hoge J, Ziolko S, Barbarich-Marsteller N, Weissfeld L, Kaye W. Increased Dopamine D2/D3 Receptor Binding After Recovery from Anorexia Nervosa Measured by Positron Emission Tomography and [11C]Raclopride. Biological Psychiatry 2005, 58: 908-912. PMID: 15992780, DOI: 10.1016/j.biopsych.2005.05.003.
- Serotonin alterations in anorexia and bulimia nervosa: New insights from imaging studiesKaye W, Frank G, Bailer U, Henry S, Meltzer C, Price J, Mathis C, Wagner A. Serotonin alterations in anorexia and bulimia nervosa: New insights from imaging studies. Physiology & Behavior 2005, 85: 73-81. PMID: 15869768, DOI: 10.1016/j.physbeh.2005.04.013.
- Relationship of a 5-HT transporter functional polymorphism to 5-HT1A receptor binding in healthy womenLee M, Bailer U, Frank G, Henry S, Meltzer C, Price J, Mathis C, Putnam K, Ferrell R, Hariri A, Kaye W. Relationship of a 5-HT transporter functional polymorphism to 5-HT1A receptor binding in healthy women. Molecular Psychiatry 2005, 10: 715-716. PMID: 15940302, DOI: 10.1038/sj.mp.4001680.
- Neurobiology of anorexia nervosa: Clinical implications of alterations of the function of serotonin and other neuronal systemsKaye W, Frank G, Bailer U, Henry S. Neurobiology of anorexia nervosa: Clinical implications of alterations of the function of serotonin and other neuronal systems. International Journal Of Eating Disorders 2005, 37: s15-s19. PMID: 15852312, DOI: 10.1002/eat.20109.
- Neuroimaging Studies in Eating DisordersFrank G, Bailer U, Henry S, Wagner A, Kaye W. Neuroimaging Studies in Eating Disorders. CNS Spectrums 2004, 9: 539-549. PMID: 15208513, DOI: 10.1017/s1092852900009639.
- Altered 5-HT2A Receptor Binding after Recovery from Bulimia-Type Anorexia Nervosa: Relationships to Harm Avoidance and Drive for ThinnessBailer U, Price J, Meltzer C, Mathis C, Frank G, Weissfeld L, McConaha C, Henry S, Brooks-Achenbach S, Barbarich N, Kaye W. Altered 5-HT2A Receptor Binding after Recovery from Bulimia-Type Anorexia Nervosa: Relationships to Harm Avoidance and Drive for Thinness. Neuropsychopharmacology 2004, 29: 1143-1155. PMID: 15054474, PMCID: PMC4301578, DOI: 10.1038/sj.npp.1300430.
- S.10.05 Role of 5HT in eating disordersKaye W, Frank G, Barbarich N, Henry S, Bailer U. S.10.05 Role of 5HT in eating disorders. European Neuropsychopharmacology 2003, 13: s121-s122. DOI: 10.1016/s0924-977x(03)91639-7.
Clinical Trials
| Conditions | Study Title |
|---|---|
| Mental Health & Behavioral Research | HPA axis function in the brains of PTSD, Trauma Exposed, or Otherwise Healthy research participants utilizing PET and MRI imaging |
| Obesity & Weight Control | Imaging cortisol metabolism in liver, adipose tissue and brain with a novel PET radioligand |